JP7712055B2 - 下部尿路上皮がんを処置する方法 - Google Patents

下部尿路上皮がんを処置する方法

Info

Publication number
JP7712055B2
JP7712055B2 JP2018558199A JP2018558199A JP7712055B2 JP 7712055 B2 JP7712055 B2 JP 7712055B2 JP 2018558199 A JP2018558199 A JP 2018558199A JP 2018558199 A JP2018558199 A JP 2018558199A JP 7712055 B2 JP7712055 B2 JP 7712055B2
Authority
JP
Japan
Prior art keywords
gemcitabine
individual
antimetabolite
pharmaceutical composition
bladder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018558199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514970A5 (cg-RX-API-DMAC7.html
JP2019514970A (ja
Inventor
デニス ギーシング，
クリストファー キューティー，
パーナナンド サルマ，
シェリル ラリビー－エルキンス，
クリストファー サーシー，
ヴィカス アガーワル，
Original Assignee
タリス バイオメディカル エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タリス バイオメディカル エルエルシー filed Critical タリス バイオメディカル エルエルシー
Publication of JP2019514970A publication Critical patent/JP2019514970A/ja
Publication of JP2019514970A5 publication Critical patent/JP2019514970A5/ja
Priority to JP2021172052A priority Critical patent/JP2022009327A/ja
Priority to JP2023206570A priority patent/JP2024028881A/ja
Application granted granted Critical
Publication of JP7712055B2 publication Critical patent/JP7712055B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
JP2018558199A 2016-05-06 2017-05-05 下部尿路上皮がんを処置する方法 Active JP7712055B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021172052A JP2022009327A (ja) 2016-05-06 2021-10-21 下部尿路上皮がんを処置する方法
JP2023206570A JP2024028881A (ja) 2016-05-06 2023-12-07 下部尿路上皮がんを処置する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662333151P 2016-05-06 2016-05-06
US62/333,151 2016-05-06
US201762443614P 2017-01-06 2017-01-06
US62/443,614 2017-01-06
PCT/US2017/031445 WO2017193098A1 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021172052A Division JP2022009327A (ja) 2016-05-06 2021-10-21 下部尿路上皮がんを処置する方法

Publications (3)

Publication Number Publication Date
JP2019514970A JP2019514970A (ja) 2019-06-06
JP2019514970A5 JP2019514970A5 (cg-RX-API-DMAC7.html) 2020-06-18
JP7712055B2 true JP7712055B2 (ja) 2025-07-23

Family

ID=60203435

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018558199A Active JP7712055B2 (ja) 2016-05-06 2017-05-05 下部尿路上皮がんを処置する方法
JP2021172052A Withdrawn JP2022009327A (ja) 2016-05-06 2021-10-21 下部尿路上皮がんを処置する方法
JP2023206570A Withdrawn JP2024028881A (ja) 2016-05-06 2023-12-07 下部尿路上皮がんを処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021172052A Withdrawn JP2022009327A (ja) 2016-05-06 2021-10-21 下部尿路上皮がんを処置する方法
JP2023206570A Withdrawn JP2024028881A (ja) 2016-05-06 2023-12-07 下部尿路上皮がんを処置する方法

Country Status (23)

Country Link
US (1) US20190388338A1 (cg-RX-API-DMAC7.html)
EP (2) EP3452053B1 (cg-RX-API-DMAC7.html)
JP (3) JP7712055B2 (cg-RX-API-DMAC7.html)
KR (2) KR102435709B1 (cg-RX-API-DMAC7.html)
CN (2) CN118453872A (cg-RX-API-DMAC7.html)
AU (1) AU2017261371B2 (cg-RX-API-DMAC7.html)
CA (1) CA3023274A1 (cg-RX-API-DMAC7.html)
ES (1) ES2940227T3 (cg-RX-API-DMAC7.html)
FI (1) FI3452053T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221544T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060965T2 (cg-RX-API-DMAC7.html)
IL (2) IL295592A (cg-RX-API-DMAC7.html)
LT (1) LT3452053T (cg-RX-API-DMAC7.html)
MX (2) MX389296B (cg-RX-API-DMAC7.html)
NZ (3) NZ787786A (cg-RX-API-DMAC7.html)
PL (1) PL3452053T3 (cg-RX-API-DMAC7.html)
PT (1) PT3452053T (cg-RX-API-DMAC7.html)
RS (1) RS64032B1 (cg-RX-API-DMAC7.html)
RU (2) RU2022100624A (cg-RX-API-DMAC7.html)
SG (2) SG10201913416PA (cg-RX-API-DMAC7.html)
SI (1) SI3452053T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300047T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017193098A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
TWI843168B (zh) 2016-10-11 2024-05-21 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
CA3071014A1 (en) * 2017-07-25 2019-01-31 Taris Biomedical Llc Methods of treating tumor metastasis
JOP20200124A1 (ar) 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512914A (ja) 2012-03-29 2015-04-30 アルター・バイオサイエンス・コーポレーション 新生物を治療するための方法
WO2015134911A1 (en) 2014-03-06 2015-09-11 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
WO2010151896A1 (en) 2009-06-26 2010-12-29 Taris Biomedical, Inc. Solid drug tablets for implantable drug delivery devices
EP2512581B1 (en) 2009-12-17 2021-02-17 TARIS Biomedical LLC Implantable device with intravesical tolerability
KR20130109025A (ko) * 2010-06-02 2013-10-07 아브락시스 바이오사이언스, 엘엘씨 방광암의 치료 방법
LT2600800T (lt) 2010-08-05 2021-01-11 Taris Biomedical Llc Ureteralinio stento pavidalo vaisto vartojimo įtaisas ir rinkinys
US9107816B2 (en) 2011-02-04 2015-08-18 Taris Biomedical Llc Implantable device for controlled dissolution and diffusion of low solubility drug
LT2890384T (lt) * 2012-08-31 2022-01-10 Taris Biomedical Llc Vaistų pateikimo sistemos ir kraujo vėžio gydymo būdai, apimantys oksaliplatiną
CA2882575C (en) 2012-08-31 2020-05-26 Dennis GIESING Drug delivery systems and methods for treatment of prostate
WO2014138214A1 (en) 2013-03-05 2014-09-12 Taris Biomedical, Inc. Drug delivery devices and methods for controlled drug release through device orifice
CN105209012B (zh) 2013-03-15 2019-02-01 塔里斯生物医药公司 用于药物递送的药物递送装置和方法
BR112015022433B1 (pt) 2013-03-15 2022-06-21 Taris Biomedical Llc Dispositivo de liberação de droga intravesical
HRP20201421T1 (hr) 2013-08-19 2020-12-11 Taris Biomedical Llc Uređaji za davanje više jedinica lijeka
AU2015279674B2 (en) 2014-06-26 2020-07-23 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
KR102658706B1 (ko) 2015-04-23 2024-04-17 타리스 바이오메디컬 엘엘씨 약물-투과성 성분을 구비한 약물 전달 장치 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512914A (ja) 2012-03-29 2015-04-30 アルター・バイオサイエンス・コーポレーション 新生物を治療するための方法
WO2015134911A1 (en) 2014-03-06 2015-09-11 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Discov. Med. (Feb 2016) vol.21, no.114, p.125-133
NCT02722538 Safety and Tolerability ofGemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer,, 2016年04月29日
Radiother. Oncol. (2012) vol.102, issue3, p.412-415

Also Published As

Publication number Publication date
RU2018142908A (ru) 2020-06-08
KR20190005204A (ko) 2019-01-15
WO2017193098A1 (en) 2017-11-09
NZ787824A (en) 2025-10-31
BR112018072551A2 (pt) 2019-02-19
EP3452053B1 (en) 2022-12-14
RS64032B1 (sr) 2023-04-28
RU2022100624A (ru) 2022-02-09
US20190388338A1 (en) 2019-12-26
NZ748252A (en) 2025-10-31
SI3452053T1 (sl) 2023-03-31
EP3452053A1 (en) 2019-03-13
SG11201809838VA (en) 2018-12-28
EP4209221A1 (en) 2023-07-12
CN109475571A (zh) 2019-03-15
PT3452053T (pt) 2023-03-03
KR102435709B1 (ko) 2022-08-25
HUE060965T2 (hu) 2023-04-28
MX2018013432A (es) 2019-08-12
KR20220123317A (ko) 2022-09-06
PL3452053T3 (pl) 2023-05-08
NZ787786A (en) 2025-10-31
EP3452053A4 (en) 2019-12-25
CA3023274A1 (en) 2017-11-09
MX389296B (es) 2025-03-20
IL262746B (en) 2022-09-01
SMT202300047T1 (it) 2023-03-17
LT3452053T (lt) 2023-02-10
HRP20221544T1 (hr) 2023-02-17
IL262746A (en) 2018-12-31
MX2021013461A (es) 2021-12-10
SG10201913416PA (en) 2020-03-30
AU2017261371A1 (en) 2018-12-13
RU2764747C2 (ru) 2022-01-20
AU2017261371B2 (en) 2023-07-06
RU2018142908A3 (cg-RX-API-DMAC7.html) 2020-08-31
IL295592A (en) 2022-10-01
CN118453872A (zh) 2024-08-09
ES2940227T3 (es) 2023-05-04
JP2019514970A (ja) 2019-06-06
JP2022009327A (ja) 2022-01-14
FI3452053T3 (fi) 2023-04-12
JP2024028881A (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
JP2024028881A (ja) 下部尿路上皮がんを処置する方法
JP7520932B2 (ja) 腫瘍転移を処置する方法
KR20200085822A (ko) 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법
HK40005970A (en) Method of treating lower tract urothelial cancer
HK40005970B (en) Method of treating lower tract urothelial cancer
BR122024005298A2 (pt) Usos de antimetabólitos no tratamento de câncer urotelial do trato inferior, kits e dispositivo de liberação
BR112018072551B1 (pt) Kits para tratamento de câncer de bexiga músculo invasivo
EA045084B1 (ru) Способы лечения и поддерживающей терапии рака мочевого пузыря с использованием гемцитабина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210813

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210813

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230301

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230301

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230314

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230418

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230425

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250710

R150 Certificate of patent or registration of utility model

Ref document number: 7712055

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150